Erika Cecon1,2,3, Julie Dam1,2,3, Marine Luka1,2,3, Clément Gautier4, Anne-Marie Chollet4, Philippe Delagrange4, Laurence Danober4, Ralf Jockers1,2,3. 1. Inserm U1016, Institut Cochin, Dept Endocrinology, Metabolism and Diabetes, Paris, France. 2. CNRS UMR 8104, Paris, France. 3. University Paris Descartes, Sorbonne Paris Cité, Paris, France. 4. Institut de Recherches SERVIER, Division Therapeutic Innovation in Neuropsychiatry, Croissy-sur-Seine, France.
Abstract
BACKGROUND AND PURPOSE: Progressive dysfunction of cholinergic transmission is a well-known characteristic of Alzheimer's disease (AD). Amyloid β (Aβ) peptide oligomers are known to play a central role in AD and are suggested to impair the function of the cholinergic nicotinic ACh receptor α7 (α7nAChR). However, the mechanism underlying the effect of Aβ on α7nAChR function is not fully understood, limiting the therapeutic exploration of this observation in AD. Here, we aimed to detect and characterize Aβ binding to α7nAChR, including the possibility of interfering with this interaction for therapeutic purposes. EXPERIMENTAL APPROACH: We developed a specific and quantitative time-resolved FRET (TR-FRET)-based binding assay for Aβ to α7nAChR and pharmacologically characterized this interaction. KEY RESULTS: We demonstrated specific and high-affinity (low nanomolar) binding of Aβ to the orthosteric binding site of α7nAChR. Aβ binding was prevented and reversed by the well-characterized orthosteric ligands of α7nAChR (epibatidine, α-bungarotoxin, methylylcaconitine, PNU-282987, S24795, and EVP6124) and by the type II positive allosteric modulator (PAM) PNU-120596 but not by the type I PAM NS1738. CONCLUSIONS AND IMPLICATIONS: Our TR-FRET Aβ binding assay demonstrates for the first time the specific binding of Aβ to α7nAChR, which will be a crucial tool for the development, testing, and selection of a novel generation of AD drug candidates targeting Aβ/α7nAChR complexes with high specificity and fewer side effects compared to currently approved α7nAChR drugs. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
BACKGROUND AND PURPOSE: Progressive dysfunction of cholinergic transmission is a well-known characteristic of Alzheimer's disease (AD). Amyloid β (Aβ) peptide oligomers are known to play a central role in AD and are suggested to impair the function of the cholinergic nicotinic ACh receptor α7 (α7nAChR). However, the mechanism underlying the effect of Aβ on α7nAChR function is not fully understood, limiting the therapeutic exploration of this observation in AD. Here, we aimed to detect and characterize Aβ binding to α7nAChR, including the possibility of interfering with this interaction for therapeutic purposes. EXPERIMENTAL APPROACH: We developed a specific and quantitative time-resolved FRET (TR-FRET)-based binding assay for Aβ to α7nAChR and pharmacologically characterized this interaction. KEY RESULTS: We demonstrated specific and high-affinity (low nanomolar) binding of Aβ to the orthosteric binding site of α7nAChR. Aβ binding was prevented and reversed by the well-characterized orthosteric ligands of α7nAChR (epibatidine, α-bungarotoxin, methylylcaconitine, PNU-282987, S24795, and EVP6124) and by the type II positive allosteric modulator (PAM) PNU-120596 but not by the type I PAM NS1738. CONCLUSIONS AND IMPLICATIONS: Our TR-FRET Aβ binding assay demonstrates for the first time the specific binding of Aβ to α7nAChR, which will be a crucial tool for the development, testing, and selection of a novel generation of AD drug candidates targeting Aβ/α7nAChR complexes with high specificity and fewer side effects compared to currently approved α7nAChR drugs. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
Authors: Luanda Pym; Mark Kemp; Valérie Raymond-Delpech; Steven Buckingham; C A R Boyd; David Sattelle Journal: Br J Pharmacol Date: 2005-12 Impact factor: 8.739
Authors: Gretchen Lopez-Hernandez; Andon N Placzek; Jeffrey S Thinschmidt; Pierre Lestage; Caryn Trocme-Thibierge; Philippe Morain; Roger L Papke Journal: Neuropharmacology Date: 2007-04-29 Impact factor: 5.250
Authors: Gareth T Young; Ruud Zwart; Alison S Walker; Emanuele Sher; Neil S Millar Journal: Proc Natl Acad Sci U S A Date: 2008-09-12 Impact factor: 11.205
Authors: Andreas Søderman; Morten S Thomsen; Henrik H Hansen; Elsebet Ø Nielsen; Morten S Jensen; Mark J West; Jens D Mikkelsen Journal: Brain Res Date: 2008-06-25 Impact factor: 3.252
Authors: Julianna L Sun; Sarah A Stokoe; Jessica P Roberts; Matheus F Sathler; Kaila A Nip; Jiayi Shou; Kaitlyn Ko; Susan Tsunoda; Seonil Kim Journal: Neurobiol Aging Date: 2019-09-19 Impact factor: 4.673